Main Uses of Quibron

Quibron is a combination medication primarily used for the management of respiratory conditions characterized by airway obstruction. It is typically prescribed to treat the symptoms of bronchial asthma, chronic bronchitis, and emphysema.

The medication works through the combined action of its two active components: theophylline and guaifenesin. Theophylline is a bronchodilator that helps to open the airways by relaxing the smooth muscles in the lungs. Guaifenesin is an expectorant that helps to thin and loosen mucus in the respiratory tract, making it easier to cough up.

Conditions Treated

• Bronchial Asthma: Quibron helps to relieve the wheezing, shortness of breath, and chest tightness associated with asthma by keeping the bronchial tubes open.
• Chronic Bronchitis: For individuals with long-term inflammation of the bronchi, the medication aids in reducing the accumulation of thick mucus and improving airflow.
• Emphysema: In cases of emphysema, where the air sacs in the lungs are damaged, Quibron assists in maintaining clearer airways to facilitate easier breathing.

Therapeutic Benefits

The primary benefit of Quibron is the dual-action approach to respiratory relief. By addressing both the physical narrowing of the airways and the presence of obstructive mucus, the medication provides a comprehensive method for managing chronic obstructive pulmonary diseases (COPD) and related conditions.

Improved Airflow

By relaxing the muscles surrounding the airways, the medication reduces the effort required to breathe. This can lead to an increase in lung capacity and a reduction in the frequency of acute respiratory distress episodes.

Mucus Clearance

The inclusion of an expectorant helps to manage the productive cough often found in chronic respiratory issues. By decreasing the viscosity of secretions, the medication helps to clear the lungs more effectively, which may reduce the feeling of congestion in the chest.

Regulatory References

1. NIH MedlinePlus overview on Theophylline

Eligibility Map: Who can and cannot use Quibron — official regulatory information

Quibron (Choline Theophyllinate) is subject to strict eligibility rules due to its narrow therapeutic index, as detailed in regulatory documents for its active component, Theophylline.

---

Eligibility Scope

• Populations for whom use is allowed (as stated in label): Use is generally established for Adults and Children (ages one and older) who do not have specific contraindications or conditions that compromise drug clearance.
• Populations for whom use is contraindicated: Use is prohibited in patients with a history of hypersensitivity to xanthine derivatives (such as Theophylline or Caffeine).

---

Age-Related Eligibility and Condition-Specific Rules

Population Group	Eligibility Status	Regulatory Basis
Older Adults (≥ 60 years)	Restricted/Caution Required. Clearance is decreased, requiring careful dose monitoring.	FDA Prescribing Information
Infants/Neonates (≤ 1 year)	Highly Restricted/Caution Required. Clearance is low and variable; intensive monitoring is mandatory.	FDA Prescribing Information
Hepatic Impairment	Restricted/Caution Required. Clearance is decreased by 50% or more (e.g., cirrhosis, acute hepatitis).	FDA Prescribing Information
Congestive Heart Failure	Restricted/Caution Required. Clearance is significantly decreased.	FDA Prescribing Information

---

Pregnancy and Other Restrictions

The FDA classifies Theophylline as Pregnancy Category C; use is permitted only if the potential benefit justifies the potential risk. The drug is excreted into human milk. Use also requires caution in patients with Active Peptic Ulcer Disease, Seizure Disorders, or Cardiac Arrhythmias due to the risk of exacerbation.

Interactions with other medicines and products

Regulatory documents establish that the interaction profile for Quibron (Choline Theophyllinate) is defined by its susceptibility to substances that alter its metabolic clearance. Theophylline is primarily metabolized by the CYP450 enzyme system, leading to numerous formally documented pharmacokinetic interactions.

Strong restrictions apply to co-administration with certain agents. The combination with Riociguat is generally not recommended by some authorities, and use with Fluvoxamine should be avoided due to significant potential to increase Theophylline plasma concentrations via enzyme inhibition. Conversely, co-administration with enzyme inducers like Rifampin or Phenytoin can increase clearance, resulting in reduced exposure.

Pharmacodynamic and Substance Interactions

Pharmacodynamic interactions are documented where Theophylline acts as an adenosine receptor antagonist, potentially reducing the efficacy of agents like Adenosine and Dipyridamole. The official label notes additive risks with Halothane, which may increase the likelihood of ventricular arrhythmias.

Non-medicinal factors, including Alcohol, Caffeine, and St. John's Wort, are formally documented to alter Theophylline clearance. Furthermore, physiological changes such as Hepatic Impairment and high fever are listed as conditions that reduce Theophylline clearance, increasing the potential for clinically significant interactions.

Enzyme Inhibition and Airway Smooth Muscle Tone

This domain focuses on Theophylline's action as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, specifically PDE III and PDE IV. This inhibition elevates intracellular cyclic AMP (cAMP) levels in airway smooth muscle cells. The resultant cascade promotes the relaxation of bronchial smooth muscle, a physiological consequence that is characterized by decreased resistance within the bronchial airways.

Modulating Purinergic and Inflammatory Pathways

In parallel, Theophylline acts as an antagonist of Adenosine receptors and modulates key inflammatory pathways by increasing the activity of Histone Deacetylase 2 (HDAC2). These actions lead to decreased airway hyper-reactivity and suppress the transcription of pro-inflammatory genes, which leads to a diminished inflammatory response and reduced tissue swelling.

Reflex-Driven Secretion and Mucus Clearance

Guaifenesin's mechanism involves initiating a vago-vagal reflex via the gastric mucosa. This nerve reflex stimulates respiratory glands, significantly increasing the volume and decreasing the viscosity of bronchial secretions. The resulting physiological effect includes the enhancement of fluid movement and transport by the mucociliary apparatus.

Official Administration Guidelines

Quibron is an oral medication that must be taken exactly as prescribed to maintain a constant, steady amount in the blood. The dosing schedule is highly individualized and determined by a healthcare provider, often requiring adjustments based on the patient's age, weight, and blood test results.

---

Administration Scope	Official Regulatory Instruction
Route & Frequency	Taken by mouth, typically once or twice daily at evenly spaced times.
Administration Technique	Extended-release tablets must be swallowed whole; they should not be broken, crushed, or chewed.
Timing in Relation to Meals	Extended-release tablets may be taken with or without food. Extended-release capsules should ideally be taken one hour before a high-fat meal or without food.
Dosing Rule	The dosage is individualized. For adults, the maximum total daily dose is typically not to exceed 600 mg/day. Dosing for children and teenagers under 45 kg is weight-based.
Missed Dose	If a dose is missed, the patient should skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses at once to make up for a missed dose.
Special Conditions	The dose requires adjustment if the patient begins or stops smoking (cigarettes or marijuana) or experiences a significant change in diet. Dosage is guided by monitoring serum theophylline concentrations (blood tests) at regular intervals.

---

This medication's use protocol is governed by a requirement for strict adherence to the prescribed frequency and schedule to ensure consistent blood concentrations. The need for therapeutic drug monitoring and physician-directed dose adjustments based on individual patient factors and lifestyle changes defines the overall official use structure.

Research evidence / Overview of Studies for Quibron (Choline Theophyllinate)

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research exploring the use of Quibron’s active ingredient, Choline Theophyllinate (Theophylline), in individuals with COPD was evaluated in Randomized Controlled Trials (RCTs), alongside broader Systematic Reviews and Observational Studies. These studies were studied for adults and older adults with stable COPD. Researchers examined outcomes related to physical discomfort and systemic functional imbalance. These included measurements of lung function, such as forced expiratory volume ( FEV1), patient-reported outcomes describing perceived discomfort, and studies monitored physiological parameters like arterial blood gas levels.

Studies observed patterns related to changes in key lung function parameters, such as FEV1, when the compound was administered, compared to a placebo. Studies also monitored changes in blood gas tensions. However, research exploring short-term changes in lung function reported that the magnitude of measured changes was generally small.

Evidence for Use in Chronic Asthma (Stable/Non-Acute)

The research foundation for the compound in chronic asthma is built upon older Randomized Controlled Trials and specific studies that monitored the compound's concentration in the body. These studies explored short-term symptom changes in adults and children whose condition was characterized by fluctuating or episodic manifestations. Researchers monitored functional measures of the airways and patient-reported outcomes describing perceived discomfort, such as wheezing and chest tightness.

Studies monitored changes in lung function measurements, such as FEV1, compared to placebo. Research describes the connection between the administered dosage and the resulting measured concentration of the compound in the bloodstream. This information contributes to understanding the concentration patterns observed in the studies.

Long-Term Studies and Follow-up Durations

Follow-up durations were limited in the primary efficacy trials, often spanning less than a year. Research provides insight into short-term changes and how symptoms evolved in the observed populations during the study period. For outcomes requiring extended observation, such as overall survival (mortality) in COPD, research has relied on Observational Cohorts. These studies, which monitored physiological parameters in patients over several years, help show what has been observed so far. However, these observational designs do not determine whether an individual will respond similarly; consequently, long-term effects are not fully established.

What Is Still Uncertain About Quibron's Evidence Base

The evidence highlights what is known—and what is still uncertain. Key limitations in the research include that comparative evidence is lacking against the newest classes of inhaled therapies. Follow-up durations were limited in many of the core studies. Studies observed that the measured changes are closely tied to the compound's concentration in the bloodstream, and this can lead to variability in observations across individuals. Research is ongoing to clarify the precise role of this compound in contemporary treatment strategies.

Key Studies & References Label: THEOPHYLLINE (ANHYDROUS)- theophylline tablet, extended release - DailyMed (FDA Clinical/PK Information)

Common questions about Quibron (FAQ)

Q: How long does it typically take for Quibron to start working or for full effects to be noticed?

A: Regulatory documents describe that the time it takes for Quibron’s active component, theophylline, to reach its highest level in the bloodstream is variable. For immediate-release oral forms, the mean peak concentration is usually reached within 1 to 2 hours. However, extended-release tablets are specifically designed to release the medicine slowly, meaning it can take much longer—often between 4 to 14 hours—for the peak effect to be observed.

Q: Does Quibron interact with common over-the-counter pain relievers like ibuprofen or aspirin?

A: Official information indicates that taking theophylline with certain pain relievers may require caution. When used alongside acetaminophen, there may be an increased potential for liver toxicity. The official product information mentions that the co-administration of theophylline with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or aspirin, may increase the potential risk of serious gastrointestinal adverse events.

Q: Does Quibron interact with birth control pills?

A: Regulatory documents state that oral contraceptive steroids (birth control pills) are known to increase the concentration of theophylline in the blood. Because of this potential interaction, monitoring serum theophylline levels may be necessary for patients, and corresponding dose adjustments may be considered by a healthcare professional.

Q: Is the extended-release (SR) formulation better for long-term use than immediate-release?

A: The extended-release formulations are pharmaceutically designed to offer a sustained action by slowly releasing the medicine into the bloodstream over a longer time, typically 12 to 24 hours. This sustained release is the basis for its use in the long-term management of chronic conditions, helping to maintain consistent levels, whereas immediate-release forms are rapidly absorbed.

Q: Can I take Quibron if I am also taking medication for depression or anxiety?

A: Official information notes that certain medications used for depression or anxiety, particularly those that act as enzyme inhibitors like fluvoxamine, can significantly reduce the body’s ability to clear theophylline. This increases the concentration of theophylline in the blood and raises the risk of toxicity. Given this potential for reduced clearance, the official documents indicate that dose adjustments and therapeutic monitoring are necessary procedures.

Q: Is there a generic version of Quibron (Theophylline) available?

A: Quibron-T is recognized as a brand name for a medication containing theophylline, the active ingredient. According to regulatory and pharmaceutical databases, there are numerous generic and other branded formulations containing the active compound theophylline currently available.

Q: Can taking Quibron affect blood sugar levels, especially for people with diabetes?

A: Studies related to theophylline’s mechanism of action indicate that it may influence the body’s glucose regulation process. This effect is most notable when theophylline is used alongside insulin. Therefore, careful monitoring of blood sugar levels is a procedure that may be required when patients with diabetes start or adjust theophylline therapy.

Q: Is Quibron used to treat sleep apnea in adults?

A: Theophylline is officially indicated for the long-term management of chronic respiratory conditions characterized by reversible airflow obstruction, such as asthma and COPD. Although limited studies exist regarding its potential role in sleep apnea syndrome, the official regulatory indications do not include this specific application. The drug is indicated for the long-term management of chronic airflow obstruction.

Q: What is the clearance time (half-life) of Quibron in the body?

A: The clearance time, or half-life, of theophylline is highly individualized and is affected by factors like smoking, age, and organ function. Official pharmacokinetic data for a healthy, non-smoking adult indicates the mean half-life is approximately 8.7 hours. Because of this high variability, therapeutic drug monitoring (blood tests) is used by prescribers to guide the individualized dosage regimen.

Q: Is Quibron safe to take alongside seasonal allergy medications or antihistamines?

A: Official information suggests that combining theophylline with certain second-generation antihistamines, such as cetirizine, carries a low risk of cumulative central nervous system effects. This could potentially lead to symptoms like increased drowsiness. Prescribers may determine that monitoring is required, as the potential for additive central nervous system effects is a possibility.

Q: How does the sustained-release coating of Quibron tablets work?

A: Extended-release tablets use specialized delivery technology, often a unique coating, to control how the medicine is released in the digestive system. This process slows and prolongs the absorption of the medicine into the bloodstream. The purpose is to maintain a steady, therapeutic concentration over a long period, typically lasting 12 to 24 hours.

Q: What should be done if asthma symptoms suddenly get worse while taking Quibron?

A: Regulatory documents specify that theophylline is intended for the long-term management of chronic respiratory symptoms. It is specifically not indicated or suitable for the quick relief of sudden, severe worsening or an acute asthma attack. Therefore, if symptoms suddenly worsen or become acute, official documents emphasize the importance of seeking immediate medical assistance.

Q: What evidence exists regarding Quibron's effect on muscle function, like the diaphragm?

A: Official documentation regarding the mechanism of action notes that theophylline increases the force of contraction of the diaphragmatic muscles. This effect is distinct from its bronchodilating action on the airway smooth muscle. This physiological effect is thought to be related to the drug’s influence on calcium regulation within those specific muscle cells.

The official labeling for Quibron, which contains theophylline, specifies strict conditions for storage and disposal to ensure stability and safety.

Storage Requirements

• Temperature Control: Store at Controlled Room Temperature, which is defined as 20 C to 25 C (68F to 77F), and protect from excessive heat, such as temperatures above 40 C (104F).
• Environmental Protection: Keep the medication in its original container, tightly closed, to protect it from moisture and maintain potency.
• Child Safety: It must be stored out of the reach and sight of children, preferably in a locked cabinet, and with the safety cap securely closed.

Disposal Instructions

Disposal should be managed using established regulatory guidelines. The preferred method is to use a community drug take-back program. If no take-back program is available, the medication should be mixed with an undesirable substance (like coffee grounds or cat litter), placed in a sealed container or bag, and discarded in the household trash. Do not flush the medication down a toilet or sink unless specifically instructed by the official product label.